AI Article Synopsis

  • The study aimed to explore the link between epigenetic age acceleration and the progression of glaucoma in patients, particularly focusing on primary open-angle glaucoma (POAG).
  • It involved a retrospective analysis of 200 POAG patients, split into those with fast and slow disease progression, assessing their epigenetic age using different DNA methylation clocks.
  • Results showed that faster progressing patients had significantly greater epigenetic age acceleration, with each year of age acceleration linked to a 15% higher chance of faster glaucoma progression.

Article Abstract

Purpose: To investigate the association between epigenetic age acceleration and glaucoma progression.

Design: Retrospective cohort study.

Participants: 100 primary open-angle glaucoma (POAG) patients with fast progression and 100 POAG patients with slow progression.

Methods: Subjects were classified as fast or slow progressors based on rates of change in standard automated perimetry (SAP) mean deviation (MD) and retinal nerve fiber layer (RNFL) thickness. Epigenetic age was calculated using the Horvath, Hannum, PhenoAge, and GrimAge clocks from DNA methylation profiles obtained from blood samples. Age acceleration (AgeAccel) was defined as the residual from a linear regression of epigenetic age on chronologic age, with positive values suggesting faster biological aging. Multivariable logistic regression models estimated the association between AgeAccel and likelihood of fast progression, adjusting for confounders.

Main Outcome Measures: Difference in epigenetic age acceleration between fast and slow glaucoma progressors.

Results: The mean rate of SAP MD change in the fastest progressing eye was -1.06 dB/year (95% CI: -1.28 to -0.85) for fast progressors compared to -0.10 dB/year (95% CI: -0.16 to -0.04) for slow progressors (P<0.001). For RNFL thickness, corresponding values were -1.60 μm/year (95% CI: -1.97 to -1.23) and -0.76 μm/year (95% CI: -1.04 to -0.48), respectively (P<0.001). Fast progressors demonstrated significantly greater age acceleration compared to slow progressors for the Horvath clock (mean difference = 2.93 years, 95% CI: 1.48 to 4.39, P<0.001) and Hannum clock (mean difference = 1.24 years, 95% CI: 0.03 to 2.46, P=0.045). In multivariable models, each year of Horvath AgeAccel was associated with 15% higher odds of fast progression (OR 1.15, 95% CI 1.07-1.23, P<0.001), after adjusting for sex, race, intraocular pressure, central corneal thickness, baseline disease severity, smoking status and follow-up time. Hannum and GrimAge clocks also showed significant associations with fast progression. The association between AgeAccel and fast progression was stronger in subjects with relatively low IOP during follow-up.

Conclusion: Accelerated epigenetic aging was associated with faster glaucoma progression. These findings suggest that faster biological age, as reflected in DNA methylation, may increase optic nerve susceptibility to damage, highlighting epigenetic age as a potential prognostic biomarker.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527091PMC
http://dx.doi.org/10.1101/2024.10.12.24315371DOI Listing

Publication Analysis

Top Keywords

epigenetic age
16
age acceleration
12
dna methylation
8
poag patients
8
fast progression
8
fast slow
8
slow progressors
8
db/year 95%
8
age
6
fast
5

Similar Publications

The Kabuki syndrome (KS) is a rare congenital disease that has two different types, KS1 and KS2, with variant in epigenetic gene KMT2D and KDM6A, respectively. It is associated with multiple abnormalities such as (developmental delay, atypical facial features, cardiac anomalies, minor skeleton anomalies, genitourinary anomalies, and mild to moderate intellectual disability). This syndrome can lead to neonatal hypoglycemia that results from hyperinsulinemia and electrolyte abnormalities.

View Article and Find Full Text PDF

How age affects human hematopoietic stem and progenitor cells and strategies to mitigate HSPC aging.

Exp Hematol

January 2025

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin, China.. Electronic address:

Hematopoietic stem cells (HSCs) are central to blood formation and play a pivotal role in hematopoietic and systemic aging. With aging, HSCs undergo significant functional changes, such as an increased stem cell pool, declined homing and reconstitution capacity, and skewed differentiation towards myeloid and megakaryocyte/platelet progenitors. These phenotypic alterations are likely due to the expansion of certain clones, known as clonal hematopoiesis (CH), which leads to disrupted hematopoietic homeostasis, including anemia, impaired immunity, higher risks of hematological malignancies, and even associations with cardiovascular disease, highlighting the broader impact of HSC aging on overall health.

View Article and Find Full Text PDF

INhibitor of Growth (ING1-5) proteins are epigenetic readers that target histone acetyltransferase (HAT) or histone deacetylase (HDAC) complexes to the H3K4Me3 mark of active transcription. ING5 targets Moz/Morf and HBO1 HAT complexes that alter acetylation of H3 and H4 core histones, affecting gene expression. Previous experiments in vitro indicated that ING5 functions to maintain stem cell character in normal and in cancer stem cells.

View Article and Find Full Text PDF

Objective: To establish a new technique to easily identify the fetal cervix-uterus complex in normal female fetuses from 20 to 40 weeks of gestation.

Material And Methods: The study was performed in routine examination in normal fetuses by two observers. Twenty-five consecutive cases per gestational week were assessed between 20 and 40 weeks.

View Article and Find Full Text PDF

Numerous diseases have been connected to protein arginine methylations mediated by protein arginine methyltransferase 5 (PRMT5). Clinical investigations of the PRMT5-specific inhibitor GSK3326595 are currently being conducted, and the results are promising for preventing cancers. However, the detailed mechanism of PRMT5 promoting colorectal cancer (CRC) malignant progression remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!